Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.

被引：0
|
作者：
Zasadny, KR
Rommelfanger, SG
Regan, DD
McCullough, NT
Kroll, S
Stagg, R
Kaminski, MS
Wahl, RL
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Coulter Pharmaceut Inc, S San Francisco, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
114
引用
收藏
页码：29P / 30P
页数：2
相关论文
共 50 条
  • [41] Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report
    Koral, KF
    Dewaraja, Y
    Clarke, LA
    Li, J
    Zasadny, KR
    Rommelfanger, SG
    Francis, IR
    Kaminski, MS
    Wahl, RL
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (04) : 347 - 355
  • [42] Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Suzuki, K
    Uike, N
    Suzumiya, J
    Kawano, F
    Takeo, T
    Okamura, S
    Sakai, C
    Mori, M
    Tamura, K
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 596S - 596S
  • [43] Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Suzumiya, J.
    Suzuki, K.
    Uike, N.
    Kawano, F.
    Takeo, T.
    Okamura, S.
    Sakai, C.
    Mori, M.
    Tamura, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Essential Role of Nuclear Medicine Technology in Tositumomab and I-131-Tositumomab Therapeutic Regimen for Non-Hodgkin's Lymphoma
    Cole, William C.
    Barrickman, Jennifer
    Bloodworth, Glen
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2006, 34 (02) : 67 - 73
  • [45] Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Cesarman, E
    Furman, RR
    Schuster, MW
    Niesvizky, R
    Muss, D
    Fiore, J
    Kroll, S
    Tidmarsh, G
    Vallabhajosula, S
    Goldsmith, SJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) : 5696 - 5704
  • [46] Tositumomab and iodine I 131 tositumomab (the BEXXAR® therapeutic regimen) shows efficacy in elderly patients (pts) with relapsed/refractory low-grade (LG), follicular, and transformed non-Hodgkin's lymphoma (NHL).
    Gregory, SA
    Zelenetz, A
    Knox, SJ
    Vose, J
    Leonard, JP
    Kaminski, M
    BLOOD, 2004, 104 (11) : 719A - 720A
  • [47] Initial experience with tositumomab and iodine I 131 tositumomab for treatment of relapsed/refractory Hodgkin lymphoma
    Jacene, Heather
    Kasamon, Yvette
    Ambinder, Richard
    Serena, Donna
    Kasecamp, Wayne
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [48] Radioimmunotherapy of non-Hodgkin's lymphoma
    Britton, KE
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (05) : 924 - 925
  • [49] Radioimmunotherapy for non-Hodgkin's lymphoma
    Friedberg, JW
    CLINICAL CANCER RESEARCH, 2004, 10 (23) : 7789 - 7791
  • [50] Safety of 131I-Rituximab Outpatient Radioimmunotherapy of Non-Hodgkin Lymphoma
    Calais, P. J.
    Turner, J. H.
    MEDICAL PHYSICS, 2011, 38 (06)
12345